CSIMarket
 
Pardes Biosciences Inc   (PRDS)
Other Ticker:  
 
 
Price: $2.1600 $0.00 0.000%
Day's High: $2.195 Week Perf: 0.93 %
Day's Low: $ 2.13 30 Day Perf: 3.1 %
Volume (M): 2,379 52 Wk High: $ 2.20
Volume (M$): $ 5,138 52 Wk Avg: $2.12
Open: $2.16 52 Wk Low: $2.06



 Market Capitalization (Millions $) 130
 Shares Outstanding (Millions) 60
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -76
 Cash Flow (TTM) (Millions $) 81
 Capital Exp. (TTM) (Millions $) 0

Pardes Biosciences Inc
Pardes Biosciences Inc is a biotechnology company that specializes in the development and commercialization of innovative bioscience products. The company focuses on areas such as molecular diagnostics, drug discovery, and personalized medicine. Pardes Biosciences aims to provide cutting-edge technologies and solutions to improve patient care and contribute to advancements in the field of biosciences.


   Company Address: 2173 Salk Avenue Carlsbad 92008 CA
   Company Phone Number: 649-8758   Stock Exchange / Ticker: NASDAQ PRDS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Pardes Biosciences Inc

PRDS Unveils Q2 2023 Financial Results, Revealing an Unexpected Operating Loss of $12.615 Million - A Twist in Pharmaceutical Industry Saga

Investors Eye Positive Surprises in Pardes Biosciences' Financial Performance
August 7, 2023
Pardes Biosciences Inc, a major pharmaceutical preparations company, has recently released its financial results for the earnings cycle of fiscal April to June 2023. While stockholders did not anticipate any modifications at the top-line, they have been closely monitoring the company's operating loss.
To the delight of investors, Pardes Biosciences reported an operating loss of $-12.615 million for the period, indicating a significant improvement when compared to the $-27.935 million loss recorded in the same quarter the previous year. This indicates that the company has been able to work more efficiently and effectively.

Pardes Biosciences Inc

Pardes Biosciences Inc: A Major Pharmaceutical Preparations Company Struggles to Overcome Financial Challenges

Pardes Biosciences Inc, a major pharmaceutical preparations company, recently reported a cumulative net loss of $-93 million for the 12 months ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -48.34%. This puts Pardes Biosciences Inc behind 201 other companies in the healthcare sector with a higher return on investmentHowever, there seems to be some improvement in the company's ROI ranking, which has progressed to 1723 in the Mar 31 2023 quarter, up from the total ROI ranking in the fourth quarter of 2022 at 4154.
Directing our attention towards the financial third quarter of 2023, Pardes Biosciences Inc reported a loss of $-0.30 per share, compared to the loss of $-0.38 per share in the previous year's reporting period, while the major pharmaceutical preparations company's previous quarter yielded a loss of $-0.25 per share.
There seems to be a steady increase in the company's losses, with a net loss of $-17.805 million in the most recent fiscal period, from a loss of $-21.440 million in the prior reporting period.
Investors will be closely watching Pardes Biosciences Inc's financial numbers when the company reports its next set of financial results on May 09, 2023.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com